Search the Newsreel

Oncolytics Biotech Inc (ONCY) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides an overview of Oncolytics Biotech Inc (ONCY) shareholder structure, detailing major individual and institutional holdings. It includes a breakdown of shareholder types, institutional shareholding trends over several quarters, and recent shareholder activity. Key individual shareholders like Kirk J Look and Thomas …

Concord Medical Services Holdings Ltd (CCM) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Concord Medical Services Holdings Ltd (CCM), including major shareholders like Morgancreek Investment Holdings, Ltd. and Solar Honor Ltd, and also lists institutional holdings over several quarters. It provides a breakdown of shareholder types by proportion and tracks …

CRDF|Cardiff Oncology Inc|Price:0.827|Chg%:-0.011

This article provides a detailed financial overview of Cardiff Oncology Inc. (CRDF), including its stock performance, key financial indicators, and historical data from income statements, balance sheets, and cash flow statements. It highlights the company's latest earnings report and future forecasts, offering investors comprehensive …

ALX Oncology Holdings Inc (ALXO) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides a detailed historical overview of ALX Oncology Holdings Inc (ALXO) stock, focusing on dividend payouts and stock splits. It indicates that ALXO has not distributed any dividends over the past five years. The page also presents current stock performance data and …

Price to sales forward of Concord Medical Services Holdings Ltd. ADR – FWB:C2C

This page from TradingView provides financial information for Concord Medical Services Holdings Ltd. ADR (FWB:C2C), specifically focusing on its price to sales forward ratio. It includes an overview of the company's financials and market data on the Frankfurt Stock Exchange. The content primarily acts …

Champions Oncology Inc (CSBR) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Champions Oncology Inc (CSBR) dividend and stock split history, indicating that no dividend data is available for the past five years. It also includes current stock price information and market capitalization for CSBR. The content appears to be …

Champions Oncology Inc (CSBR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a brief overview of Champions Oncology Inc (CSBR), including its stock performance and market cap. It highlights that detailed revenue breakdown data by business segment and region has not yet been disclosed by the company, though it lists United States revenue …

BridgeBio Oncology Therapeutics Ord Shs (BBOT) Institutional Confidence

The article provides an overview of institutional confidence in BridgeBio Oncology Therapeutics Ord Shs (BBOT) by listing the top institutional shareholders and their shareholdings. It details the number of shares held by major investment firms such as Cormorant Asset Management, BridgeBio Pharma, and Deerfield …

BridgeBio Oncology Therapeutics Ord Shs (BBOT) Earnings Forecast: Future EPS & Revenue Growth Estimates

The article provides an earnings forecast for BridgeBio Oncology Therapeutics Ord Shs (BBOT), highlighting analyst ratings, target price, and expected EPS and revenue growth. Based on 11 analysts, the stock has a "Buy" trend with a significant upside space. The document also includes a …

Concord Medical Services Holdings Ltd (CCM) Financial Health: Profitability & Balance Sheet Analysis

This article provides a financial analysis of Concord Medical Services Holdings Ltd (CCM), focusing on its profitability and balance sheet. It presents the stock's current trading price, market capitalization, and a general overview of available financial information. The content also notes the stock performance …

TradingKey

This article provides a cash flow statement analysis for Concord Medical Services Holdings Ltd (CCM). It details operating, investing, and financing cash flows, including figures for capital expenditures and free cash flow. The article also includes FAQs explaining what each type of cash flow …

Granahan Investment Management LLC Buys Shares of 231,040 BridgeBio Oncology Therapeutics, Inc $BBOT

Granahan Investment Management LLC has acquired 231,040 shares of BridgeBio Oncology Therapeutics (NASDAQ:BBOT) during the first quarter, now holding a 0.29% stake valued at approximately $2.07 million. Other institutional investors have also increased their positions, with hedge funds and institutions collectively owning 54.89% of …

Concord Medical Services Holdings Ltd (CCM) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Concord Medical Services Holdings Ltd (CCM), focusing on various financial metrics. It details volatility measures like Beta, VaR, and Maximum Drawdown over different periods, alongside return figures and Sharpe Ratios. The assessment also includes liquidity indicators such …

BBOT Q1 2026 Earnings: Narrower Loss Beats Estimates as Pipeline Advances - Tangible Book Value

ALXO Balance Sheet

This article provides a detailed balance sheet analysis for ALX Oncology Holdings Inc (ALXO), presenting quarterly and annual financial data spanning several years for various assets, liabilities, and shareholders' equity categories. It allows users to evaluate the company's financial health and understand key financial …

ALXO|ALX Oncology Holdings Inc|Price:2.030|Chg%:+0.010

ALX Oncology Holdings Inc. (ALXO) is a clinical-stage biotechnology company with a strong growth potential, despite relatively weak fundamentals. The stock is considered fairly valued and has a high institutional ownership. Analysts rate it as a "Buy" with a target price of $4.60, indicating …

Citius Oncology Inc (CTOR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The article discusses the revenue breakdown for Citius Oncology Inc (CTOR), noting that relevant data regarding business segments and regional revenue and profit contribution have not yet been disclosed by the company. It highlights the company's current stock price, market cap, and links to …

Cardiff Oncology, Inc. Revenue Breakdown – NASDAQ:CRDF

Cardiff Oncology, Inc. (NASDAQ: CRDF) generated $593,000 USD in revenue last year from its top-performing segment, Novel Therapies for Cancers, a decrease from $683,000 USD in the prior year. All of the company's revenue last year came from the United States.

BBOT|BridgeBio Oncology Therapeutics Ord Shs|Price:8.820|Chg%:+0.100

This article provides a detailed financial overview of BridgeBio Oncology Therapeutics Ord Shs (BBOT), including its current stock price, market capitalization, P/E ratio, and recent performance. It also covers analyst ratings, key indicators, major shareholders, and comparisons with peer companies in the pharmaceutical sector. …

Enterprise value to EBITDA forward of Champions Oncology, Inc. – MUN:2I3

The article discusses the Enterprise Value to EBITDA forward for Champions Oncology, Inc. (MUN:2I3) as traded on the Munich Stock Exchange. It appears to be a financial data point from a TradingView search, indicating a specific valuation metric for the company. The content itself …

CG Oncology Inc (CGON) Income Statement

This article presents the quarterly and annual income statements for CG Oncology Inc (CGON), offering detailed financial data such as revenue, operating expenses, and net income. It covers fiscal years from FY2022Q4 to FY2026Q1, providing insights into the company's financial performance and operational efficiency. …

Concord Biotech Ltd. Revenue Breakdown – NSE:CONCORDBIO

TOI|Oncology Institute Inc|Price:4.980|Chg%:-0.090

Oncology Institute Inc (TOI) is trading at $4.980, down 1.78%, with a high growth potential and stable fundamentals. Analysts maintain a "Buy" rating with a target price of $8.40, suggesting a significant upside. Despite institutional selling in the last quarter, the company's revenue has …

PYXS|Pyxis Oncology Inc|Price:3.020|

Why Did KURA Stock Jump 13% In Pre-Market Today?

Kura Oncology (KURA) shares surged over 13% in pre-market trading after the biotech firm reported encouraging early data from its ongoing trial for advanced kidney cancer. The trial for its investigational therapy, Darlifarnib, in combination with Cabozantinib, showed a 44% objective response rate and …

CG Oncology Inc (CGON) Institutional Confidence

The article analyzes the institutional confidence score for CG Oncology Inc (CGON), which is currently 10.00, placing it first in the Biotechnology & Medical Research industry. Institutional shareholding decreased by 9.96% quarter-over-quarter, with Bill Nygren | OAKMX identified as the largest institutional shareholder despite …

Kura Oncology Inc (KURA) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Kura Oncology Inc (KURA), stating its current valuation score is 6.69, ranking 304 out of 386 in the Biotechnology & Medical Research industry. It details the company's current P/E ratio, noting its fluctuation compared to recent highs …

Kura Oncology Inc (KURA) Institutional Confidence

Kura Oncology Inc (KURA) shows a high institutional confidence score of 10.00, placing it 1st within the Biotechnology & Medical Research industry. Institutional ownership stands at 103.35%, indicating a quarterly increase of 4.16%. While James Simons is listed as the largest shareholder by percentage, …

Champions Oncology, Inc. Revenue Breakdown – MUN:2I3

Champions Oncology, Inc. (MUN:2I3) generated €50.28 million in revenue last year, primarily from its Pharmacology Services segment (€42.90 million), a decrease from the previous year. The majority of this revenue, €50.28 million, came from the United States, compared to €47.03 million in the prior …

Champions Oncology Inc (CSBR) Institutional Confidence

Champions Oncology Inc (CSBR) has an institutional shareholding score of 3.00, placing it 192nd out of 386 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 47.97%, showing a quarter-over-quarter decrease of 7.89%. James Simons is the largest institutional shareholder, …

Cardiff Oncology Inc (CRDF) Valuation: PE, PB & Fair Value Analysis

Cardiff Oncology Inc (CRDF) currently holds a valuation score of 6.15, placing it 356th out of 386 in the Biotechnology & Medical Research industry. Its P/E ratio stands at -1.24, which is significantly lower than its recent high and higher than its recent low. …

Cardiff Oncology Inc (CRDF) Institutional Confidence

Cardiff Oncology Inc (CRDF) has an institutional shareholding score of 3.00, placing it 192nd in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 35.32%, a significant decrease of 33.21% quarter-over-quarter. James Simons is the largest institutional shareholder, holding 0.15% of shares …

BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) has received a "Moderate Buy" consensus recommendation from brokerages, based on seven buy ratings and one sell rating. The average 1-year price target is $24.80, significantly above its current trading price of $8.82. The company, which is focused on developing …

Citius Oncology Inc (CTOR) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Citius Oncology Inc (CTOR), listing its major shareholders and their respective proportions. It also provides a breakdown of shareholder types, including corporations, hedge funds, and individual investors. Additionally, the article presents historical institutional shareholding data and recent …

Champions Oncology (CSBR) Q2 2026 Earnings: EPS Misses Estimates as Stock Gains 2.17% - Gross Profit Margin

Champions Oncology (CSBR) Q2 2026 Earnings: EPS Misses Estimates as Stock Gains 2.17% - Guidance Update